ATE307886T1 - Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung - Google Patents

Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung

Info

Publication number
ATE307886T1
ATE307886T1 AT96943177T AT96943177T ATE307886T1 AT E307886 T1 ATE307886 T1 AT E307886T1 AT 96943177 T AT96943177 T AT 96943177T AT 96943177 T AT96943177 T AT 96943177T AT E307886 T1 ATE307886 T1 AT E307886T1
Authority
AT
Austria
Prior art keywords
tsap
tsip
sequence
medications
proteins
Prior art date
Application number
AT96943177T
Other languages
English (en)
Inventor
Adam Telerman
Robert Amson
Daniel Cohen
Original Assignee
Cerenis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9515146A external-priority patent/FR2742766B1/fr
Priority claimed from FR9604853A external-priority patent/FR2747691B1/fr
Application filed by Cerenis filed Critical Cerenis
Application granted granted Critical
Publication of ATE307886T1 publication Critical patent/ATE307886T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
AT96943177T 1995-12-20 1996-12-20 Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung ATE307886T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9515146A FR2742766B1 (fr) 1995-12-20 1995-12-20 Sequences nucleotidiques, proteines, medicaments et agents diagnostics utiles dans le traitement du cancer
FR9604853A FR2747691B1 (fr) 1996-04-18 1996-04-18 Acides nucleiques et proteines utiles a titre d'agent anticancereux et antiviral
PCT/FR1996/002061 WO1997022695A2 (fr) 1995-12-20 1996-12-20 Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer

Publications (1)

Publication Number Publication Date
ATE307886T1 true ATE307886T1 (de) 2005-11-15

Family

ID=26232392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96943177T ATE307886T1 (de) 1995-12-20 1996-12-20 Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung

Country Status (6)

Country Link
EP (1) EP0868512B9 (de)
JP (1) JP2000502893A (de)
AT (1) ATE307886T1 (de)
CA (1) CA2240449A1 (de)
DE (1) DE69635349T2 (de)
WO (1) WO1997022695A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768346B1 (fr) 1997-09-15 2002-04-19 Fond Jean Dausset Ceph Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic
FR2782085B1 (fr) * 1998-08-05 2002-12-13 Fond Jean Dausset Ceph Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus
JP2003529321A (ja) * 1999-04-29 2003-10-07 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション Ｐ−ｈｙｄｅファミリーの単離された核酸、ｐ−ｈｙｄｅタンパク質、及び癌における細胞死の誘導に対する感受性を誘導する方法
US6835812B1 (en) 1999-04-29 2004-12-28 University Of Tennessee Research Corporation Human p-Hyde proteins
US7087386B2 (en) 1999-06-11 2006-08-08 The Burnham Institute Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
JP2003502042A (ja) * 1999-06-11 2003-01-21 ザ バーナム インスティチュート タンパク質分解に関連するタンパク質をコードする核酸、それに関係する産物および方法
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
US6638734B1 (en) 1999-06-11 2003-10-28 The Burnham Institute Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
CN1314359A (zh) * 2000-03-17 2001-09-26 上海博德基因开发有限公司 一种新的多肽——肿瘤抑制因子63和编码这种多肽的多核苷酸
EP1297186A4 (de) * 2000-06-30 2005-06-29 Univ Utah Res Found Methode zum durchmustern für chemotherapeutische krebstherapien
FR2818661A1 (fr) * 2000-12-26 2002-06-28 Molecular Engines Laboratoires Gene implique dans la regulation de l'apoptose
CA2432327A1 (fr) * 2000-12-26 2002-07-04 Molecular Engines Laboratories Procede de criblage base sur les partenaires de liaison de tsap6
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025176A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025177A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
JP4536588B2 (ja) * 2005-05-11 2010-09-01 財団法人宮崎県産業支援財団 成人ｔ細胞白血病の診断器具

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5659024A (en) * 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death

Also Published As

Publication number Publication date
JP2000502893A (ja) 2000-03-14
EP0868512A2 (de) 1998-10-07
DE69635349D1 (de) 2005-12-01
WO1997022695A2 (fr) 1997-06-26
EP0868512B9 (de) 2006-09-06
WO1997022695A3 (fr) 1997-09-18
CA2240449A1 (fr) 1997-06-26
EP0868512B1 (de) 2005-10-26
DE69635349T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
WO1999033998A3 (de) Regulatorische dna-sequenzen des gens der humanen katalytischen telomerase-untereinheit und deren diagnostische und therapeutische verwendung
WO1998059040A3 (de) Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
BR9700957A (pt) Proteína de hormónio de crescimento humano mutante deoxiribonucleotídeo peptídeo de uma proteína plasmídeo de expressão produto anticorpo medicamentos para o tratamento de gigantismo e acromegalia e para terapia genética
EP1169441B8 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
AP2000001999A0 (en) Gene therapy method.
EP0815233A4 (de) Neue cytokinine aus vögeln und dafür codierende genetische sequenzen
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
NZ332586A (en) Suppression of endogenous gene and replacement of suppressed gene sequence
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
DE69712907D1 (de) Immunogene tlp-zusammensetzung
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
WO1999042137A3 (en) Stress promoter control of therapeutic genes in gene therapy: compositions and methods
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
BR9908518A (pt) Utilização do fator de crescimento de monócitos cd137 ou de um análogo funcional do mesmo, processos in vitro para promover a proliferação de monócitos periféricos, para o tratamento regenerativo de pacientes de quimioterapia ou de terapia com radiação, e para promover a defesa imunológica não-especìfica endógena, utilização de uma sequencia de nucleotìdeos que codifica para cd137 ou um análogo funcional do mesmo, composição de terapia de genes, e, processo de terapia de genes para o tratamento de um dos distúrbios
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties